ADMA Biologics, Inc. (ADMA)

2.0500 -0.0400 (-1.91%) As of 3:23PM EST. Market open.

ADMA Biologics, Inc.

465 State Route 17
Ramsey, NJ 07446
United States
201 478 5552
http://www.admabiologics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 313

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Adam S. Grossman	Co-Founder, Pres, CEO & Director	941.16k	N/A	1977
Dr. Jerrold B. Grossman Ph.D., D.P.S.	Co-Founder & Vice Chairman	70.9k	N/A	1948
Mr. Brian Lenz CPA, CPA	Exec. VP & CFO	741.73k	N/A	1972
Dr. James Mond	Exec. VP, Chief Scientific Officer & Chief Medical Officer	856.99k	N/A	1946
Ms. Kim Tripodo	Exec. Director & Head of Human Resource and Admin. Operations	N/A	N/A	N/A
Mr. Skyler Bloom	Director of Investor Relations & Corp. Strategy	N/A	N/A	N/A
Ms. Kaitlin Kestenberg	VP of Compliance, Project Management & Clinical Operations	N/A	N/A	N/A
Mr. Michael Least	VP of Sales & Commercial Operations	N/A	N/A	N/A
Mr. Drew Pantello	VP of Marketing & Corp. Devel.	N/A	N/A	N/A
Dr. Gene A. Wetzstein BCOP, Pharm.D.	Exec. Director & Head of Scientific Engagement	N/A	N/A	N/A

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Corporate Governance

ADMA Biologics, Inc.’s ISS Governance QualityScore as of December 3, 2020 is 8. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 9; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.